

Pembrolizumab KEYNOTE-048

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-048

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Head and neck cancer  
 Therapeutic Indication: First-line treatment of patients with metastatic or unresectable, recurrent SCCHN  
 Experimental Arm: Pembrolizumab + Cisplatin or carboplatin/5-FU  
 Control Arm: Cisplatin or carboplatin/5-FU/cetuximab

